An observational study to identify the prevalence of thrombocytopenia and anti‐PF4/polyanion antibodies in Norwegian health care workers after COVID‐19 vaccination

BACKGROUND: The COVID‐19 vaccine from AstraZeneca (AZD1222) is one of several vaccines introduced to provide immunity against SARS‐CoV‐2. Recently, more than 50 cases have been reported presenting a combination of thrombosis, thrombocytopenia, and remarkably high levels of anti‐platelet factor 4 (PF...

Descripción completa

Detalles Bibliográficos
Autores principales: Sørvoll, Ingvild Hausberg, Horvei, Kjersti Daae, Ernstsen, Siw Leiknes, Lægreid, Ingvild Jenssen, Lund, Svetlana, Grønli, Renathe Henriksen, Olsen, Magnus Kringstad, Jacobsen, Hege Karine, Eriksson, Anna, Halstensen, Anne Marie, Tjønnfjord, Eirik, Ghanima, Waleed, Ahlen, Maria Therese
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Journal of Thrombosis and Haemostasis published by ELSEVIER INC. on behalf of International Society on Thrombosis and Haemostasis 2021
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8237070/
https://www.ncbi.nlm.nih.gov/pubmed/33909350
http://dx.doi.org/10.1111/jth.15352

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8237070/
https://www.ncbi.nlm.nih.gov/pubmed/33909350
http://dx.doi.org/10.1111/jth.15352

Ejemplares similares